ScripAfter years of wondering whether founder and executive chairman Vivek Ramaswamy would take Roivant Sciences public, the multi-subsidiary firm will begin trading on the Nasdaq in the third quarter wh
ScripSix biopharmaceutical companies traveled down a path toward the US stock market during the first week of May, but half took the initial public offering route and the other half decided to go public by